Primary Human Immune Cells

ATCC primary immune cells are able to support complex, physiologically relevant research projects, including toxicity screening, transplantation and graft rejection, inflammation and allergy, vaccine, drug development, and cancer immunology studies.
  • High differentiation capacity or immune activity
  • Expansion or differentiation protocols 
  • Functional data available
  • Greater than 90% purity for select biomarkers
  • Diverse pool of donors available
  • Positive and negative biomarkers
  • Greater than 80% cryo-recovery
  • Normal cell morphology
  • Use the selection guide to find the primary immune cells that you need:

    Cell Type ATCC® No. Cells/vial  Positive Biomarkers
    Peripheral Blood CD14+ Monocytes PCS-800-010™ 50 million CD14, CD45
    Peripheral Blood Mononuclear Cells PCS-800-011™ 25 million CD45
    Bone Marrow CD34+ Cells PCS-800-012™ 500,000 CD34, CD45
    Bone Marrow Mononuclear Cells PCS-800-013™ 25 million CD45
    Cord Blood CD34+ Cells PCS-800-014™ 500,000 CD34, CD45
    New! Peripheral Blood CD4+ Helper T Cells PCS-800-016™ 25 million CD3, CD4, CD45
    New! Peripheral Blood CD8+ Cytotoxic T Cells PCS-800-017™ 25 million CD3, CD8, CD45
    New! Peripheral Blood CD19+ B Cells PCS-800-018™ 25 million CD20, CD45
    New! Peripheral Blood CD56+ Natural Killer Cells PCS-800-019™ 5 million CD45, CD56

    Human Primary Immune Cells Flyer

    Bone marrow and cord blood CD34+ hematopoietic progenitor stem cells give rise to the more differentiated components of the immune system. Peripheral CD14+ cells differentiate into dendritic cells or macrophages. Mononuclear cells from bone marrow or peripheral blood include differentiated macrophages, dendritic cells, monocytes, lymphocytes, and a small fraction of hematopoietic cells. CD4+, CD8+, and CD19+ cells are important components of the adaptive immune system, while CD56+ natural killer cells are critical effectors of the innate immune system.

    Download our Human Primary Immune Cell Flyer to learn more (Coming soon)